Annotation Detail
Information
- Associated Genes
- FGFR3
- Associated Variants
-
FGFR3 MUTATION
FGFR3 MUTATION - Associated Disease
- bladder carcinoma
- Source Database
- CIViC Evidence
- Description
- Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. In the subgroup of eight patients with FGFR3-mutated bladder/urothelial cancer treated at doses ≥ 100 mg, the disease control rate (SD + PR) was 75%. 3 patients achieved PRs and 3 patients had SD. Of the six patients with disease control, the time on treatment ranged from 15.1 to ≥ 101 weeks, with one ongoing at data cutoff.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1910
- Gene URL
- https://civic.genome.wustl.edu/links/genes/23
- Variant URL
- https://civic.genome.wustl.edu/links/variants/827
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Bladder Carcinoma
- Evidence Direction
- Supports
- Drug
- Infigratinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 27870574
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Infigratinib | Sensitivity | true |